Medicus Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Key Highlights
- ➤Pfizer licensed CD228V worldwide; provided $2.0 million development funding.
- ➤SkinJect LOI contemplates approximately $135 million pre-money enterprise valuation.
- ➤Cash and equivalents $5.0 million versus $8.7 million at December 31, 2025.
- ➤Net loss $15.2 million versus $16.0 million in Q3 2025.
- ➤Teverelix proposed Phase 2b/3 protocol targets approximately 608 patients, pending FDA feedback.
Expert Statements
Raza Bokhari, Executive Chairman and CEO of Medicus
“The third quarter saw the transformation of Medicus into a precision oncology-led biotech company with CD228V as our principal development priority.”
Raza Bokhari, Executive Chairman and CEO of Medicus
“With capital-efficient allocation of resources, we remain focused on disciplined execution, regulatory excellence and strategic growth as we seek to build long-term shareholder value and advance therapies with the potential to improve patient outcomes.”
PHILADELPHIA, PA / ACCESS Newswire / November 6, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today reported financial results for the three and nine months ended September 30, 2026, and provided a business update highlighting capital efficient strategic, clinical and regulatory progress across its development portfolio.
During the third quarter of 2026, Medicus entered into a co-development and license agreement with Pfizer Inc. ("Pfizer") for PF-08046031 (CD228V), a clinical-stage antibody-drug conjugate (ADC) targeting melanotransferrin, or CD228. The Company subsequently designated CD228V as its principal development priority, with an initial focus on establishing clinical proof-of-concept in melanoma.
Get started
Create a free account to read the full story.